JP2013505265A5 - - Google Patents

Download PDF

Info

Publication number
JP2013505265A5
JP2013505265A5 JP2012529958A JP2012529958A JP2013505265A5 JP 2013505265 A5 JP2013505265 A5 JP 2013505265A5 JP 2012529958 A JP2012529958 A JP 2012529958A JP 2012529958 A JP2012529958 A JP 2012529958A JP 2013505265 A5 JP2013505265 A5 JP 2013505265A5
Authority
JP
Japan
Prior art keywords
compound
cdcl
nmr
mhz
procedure similar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012529958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505265A (ja
JP5795766B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/049471 external-priority patent/WO2011035231A1/en
Publication of JP2013505265A publication Critical patent/JP2013505265A/ja
Publication of JP2013505265A5 publication Critical patent/JP2013505265A5/ja
Application granted granted Critical
Publication of JP5795766B2 publication Critical patent/JP5795766B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012529958A 2009-09-21 2010-09-20 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体 Active JP5795766B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24429709P 2009-09-21 2009-09-21
US61/244,297 2009-09-21
PCT/US2010/049471 WO2011035231A1 (en) 2009-09-21 2010-09-20 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015098728A Division JP6033362B2 (ja) 2009-09-21 2015-05-14 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体

Publications (3)

Publication Number Publication Date
JP2013505265A JP2013505265A (ja) 2013-02-14
JP2013505265A5 true JP2013505265A5 (OSRAM) 2014-12-25
JP5795766B2 JP5795766B2 (ja) 2015-10-14

Family

ID=43031517

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012529958A Active JP5795766B2 (ja) 2009-09-21 2010-09-20 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体
JP2015098728A Active JP6033362B2 (ja) 2009-09-21 2015-05-14 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体
JP2016207475A Withdrawn JP2017075146A (ja) 2009-09-21 2016-10-24 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015098728A Active JP6033362B2 (ja) 2009-09-21 2015-05-14 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体
JP2016207475A Withdrawn JP2017075146A (ja) 2009-09-21 2016-10-24 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体

Country Status (32)

Country Link
EP (2) EP3150608B1 (OSRAM)
JP (3) JP5795766B2 (OSRAM)
KR (2) KR101818779B1 (OSRAM)
CN (1) CN102596958A (OSRAM)
AP (1) AP2012006189A0 (OSRAM)
AU (4) AU2010295373B2 (OSRAM)
BR (3) BR122021012877B8 (OSRAM)
CA (1) CA2773772C (OSRAM)
CL (1) CL2012000707A1 (OSRAM)
CR (2) CR20190103A (OSRAM)
CY (1) CY1118605T1 (OSRAM)
DK (1) DK2480552T3 (OSRAM)
EA (1) EA201200525A1 (OSRAM)
EC (1) ECSP12011817A (OSRAM)
ES (2) ES2730805T3 (OSRAM)
HR (1) HRP20170197T1 (OSRAM)
HU (1) HUE032252T2 (OSRAM)
IL (2) IL218599A (OSRAM)
LT (1) LT2480552T (OSRAM)
ME (1) ME02656B (OSRAM)
MX (1) MX352646B (OSRAM)
NZ (1) NZ599402A (OSRAM)
PE (3) PE20210668A1 (OSRAM)
PL (1) PL2480552T3 (OSRAM)
PT (1) PT2480552T (OSRAM)
RS (1) RS55699B1 (OSRAM)
SG (1) SG179194A1 (OSRAM)
SI (1) SI2480552T1 (OSRAM)
SM (2) SMT201700091T1 (OSRAM)
UA (1) UA110466C2 (OSRAM)
WO (1) WO2011035231A1 (OSRAM)
ZA (1) ZA201202175B (OSRAM)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3237884B2 (ja) 1991-12-27 2001-12-10 株式会社コーセー 美爪料
HRP20130048T1 (hr) 2008-04-23 2013-02-28 Gilead Sciences, Inc. Karba-nukleozidni analozi za antivirusnu terapiju
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
JP6104504B2 (ja) 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
TW201026715A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
AU2010295373B2 (en) * 2009-09-21 2016-09-29 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US7973013B2 (en) * 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2011035250A1 (en) 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
CL2011000716A1 (es) * 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
EA025311B1 (ru) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
TW201305185A (zh) * 2010-09-13 2013-02-01 吉李德科學股份有限公司 用於抗病毒治療之2’-氟取代之碳-核苷類似物
PE20131165A1 (es) * 2010-09-20 2013-10-14 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
TWI556840B (zh) 2010-11-19 2016-11-11 吉李德科學股份有限公司 治療用組成物
AU2011349844B2 (en) 2010-12-20 2017-06-01 Gilead Sciences, Inc. Combinations for treating HCV
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
SI2709613T2 (sl) 2011-09-16 2020-12-31 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Postopki za zdravljenje HCV
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的3’,5’-環磷酸酯及用於治療病毒感染之醫藥組成物
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
KR102068856B1 (ko) * 2012-03-13 2020-01-21 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료를 위한 2'-치환된 카바-뉴클레오시드 유사체
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
EP2909210A4 (en) * 2012-10-17 2016-04-06 Merck Sharp & Dohme 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
WO2014059901A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
WO2014078463A1 (en) 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. 2 -alkynyl substituted nucleoside derivatives for treating viral diseases
NZ729172A (en) 2013-01-31 2018-06-29 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US9765107B2 (en) 2013-06-18 2017-09-19 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
EP3083654A1 (en) * 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類
US10526363B2 (en) 2014-08-15 2020-01-07 Merck Sharp & Dohme Corp. Substituted phosphoramidate compounds and uses thereof
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 2’-氯胺基嘧啶酮及嘧啶二酮核苷類
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
IL296496B2 (en) 2014-12-26 2024-10-01 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US10618926B2 (en) 2015-04-02 2020-04-14 Merck Sharp & Dohme Process for making phosphoramidate protected nucleoside compounds
CN104945437B (zh) * 2015-05-19 2017-03-01 广州诺威生物技术有限公司 一种嘧啶类新化合物
HRP20220355T1 (hr) 2015-09-16 2022-05-13 Gilead Sciences, Inc. Postupci za liječenje infekcija coronaviridae
AU2017231824B2 (en) 2016-03-09 2021-07-01 Alios Biopharma, Inc. Acyclic antivirals
CN114456176B (zh) 2016-03-28 2024-08-30 因赛特公司 作为tam抑制剂的吡咯并三嗪化合物
CN106083962B (zh) * 2016-06-08 2018-12-18 成都倍特药业有限公司 一种具有环磷酰胺结构的化合物及其制备方法
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
JP7051804B2 (ja) * 2016-07-14 2022-04-11 エフ.ホフマン-ラ ロシュ アーゲー 感染症の治療のための6,7-ジヒドロ-4H-ピラゾロ[1,5-a]ピラジン化合物と6,7-ジヒドロ-4H-トリアゾロ[1,5-a]ピラジン化合物
US20190169221A1 (en) * 2016-08-12 2019-06-06 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN116036112A (zh) 2017-03-14 2023-05-02 吉利德科学公司 治疗猫冠状病毒感染的方法
WO2018204198A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP4512475A3 (en) 2017-07-11 2025-05-14 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
CA3075950A1 (en) * 2017-09-18 2019-03-21 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
JP7637328B2 (ja) 2019-02-07 2025-02-28 ベイジーン リミテッド Tlr7アゴニストとしてのイミダゾ[2,1-f][1,2,4]トリアジン-4-アミン誘導体
AU2020267486B2 (en) 2019-05-09 2025-12-18 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as STING modulators
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI791193B (zh) 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
CN118994170A (zh) 2020-03-12 2024-11-22 吉利德科学公司 制备1'-氰基核苷的方法
EP4132651B1 (en) 2020-04-06 2026-03-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
CA3187821A1 (en) 2020-06-24 2021-12-30 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
WO2022038539A2 (en) 2020-08-18 2022-02-24 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds
MX2023002233A (es) 2020-08-24 2023-03-15 Gilead Sciences Inc Compuestos fosfolipidos y usos de estos.
WO2022047065A2 (en) 2020-08-27 2022-03-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
US20240228521A1 (en) * 2021-04-14 2024-07-11 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds, and uses thereof
JP7688152B2 (ja) 2021-04-16 2025-06-03 ギリアード サイエンシーズ, インコーポレイテッド アミドを使用してカルバヌクレオシドを調製する方法
JP2024518530A (ja) * 2021-05-14 2024-05-01 ビーエム ファーマ コンサルティング ピーティーワイ リミテッド ウイルス感染の予防及び治療のための二環式複素環化合物
JP7719954B2 (ja) 2021-08-18 2025-08-06 ギリアード サイエンシーズ, インコーポレイテッド リン脂質化合物並びにその製造方法及び使用方法
TW202525810A (zh) 2022-03-02 2025-07-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
CA3256146A1 (en) * 2022-04-25 2025-07-03 Miracure Biotechnology Limited NUCLEOSIDE MEDICINE FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION, AND ITS USE
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
AU651835B2 (en) 1990-06-13 1994-08-04 Arnold Glazier Phosphorous prodrugs
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
JP2004533406A (ja) 2000-10-18 2004-11-04 フアーマセツト・リミテツド ウイルス感染症および異常細胞増殖を治療するための修飾ヌクレオシド
SI1355916T1 (sl) * 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
EP1438054A4 (en) 2001-09-28 2006-07-26 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION
RU2005118421A (ru) 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-разветвленные нуклеозиды и мутация flaviviridae
MX2007003085A (es) 2004-09-14 2007-08-02 Pharmasset Inc Preparacion de 2'-fluoro-2'-alquilo sustituido u otras ribofuranosil pirimidinas y purinas opcionalmente sustituidas y sus derivados.
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA-依赖性RNA病毒感染的氟化吡咯并[2,3-d]嘧啶核苷
AU2005317081A1 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
TW200720285A (en) * 2005-04-25 2007-06-01 Genelabs Tech Inc Nucleoside compounds for treating viral infections
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤
WO2008005542A2 (en) * 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
US7951789B2 (en) * 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US8071568B2 (en) 2007-01-05 2011-12-06 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
SI2114980T1 (sl) * 2007-01-12 2012-11-30 Biocryst Pharm Inc Protivirusni nukleozidni analogi
JP2010522241A (ja) 2007-03-21 2010-07-01 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物
AU2008251555B2 (en) 2007-05-10 2012-08-30 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-D] dioxolane compounds for use in the treatment of viral infections and cancer
US8227431B2 (en) * 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
HRP20130048T1 (hr) * 2008-04-23 2013-02-28 Gilead Sciences, Inc. Karba-nukleozidni analozi za antivirusnu terapiju
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
AU2010295373B2 (en) * 2009-09-21 2016-09-29 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2011035250A1 (en) * 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs

Similar Documents

Publication Publication Date Title
JP2012527477A5 (OSRAM)
TWI367206B (en) Process for the preparation of prostaglandin analogues and intermediates thereof
IL246265B (en) A method for the production of intermediates for the preparation of 5-fluoro-h1-pyrazolopyridines and such compounds
PL2281792T3 (pl) Sposób otrzymywania związków fluorowych
EP3392368B8 (en) Use of beta-fesi2 phase material as a solar-thermal conversion member and method of producing it
JP2013532130A5 (OSRAM)
JP2010241791A5 (OSRAM)
HUE066392T2 (hu) Eljárás fluoralkil-fluorformiát elõállítására
IL220936A0 (en) Process for the synthesis of lacosamide
EP3444238A3 (en) Process for preparing difluoromethylene compounds
EP2310347A4 (en) PROCESS FOR THE PREPARATION OF PERFLUORATED CIS-ALKEN
JP2012094862A5 (OSRAM)
JP2011519871A5 (OSRAM)
JP2010209099A5 (OSRAM)
IL223066A0 (en) New process for the synthesis of tapentadol and intermediates thereof
IL219913A0 (en) New process for the preparation of tapentadol and intermediates thereof
IL225557A (en) Preparation Method (3s, 3s) 4,4'-Disulfandylbis (3-Aminobutane 1 - Sulfonic Acid)
BR112012017828A2 (pt) ''método para a produção de um produto químico por fermentação contínua''
JP2012250569A5 (OSRAM)
ITBS20100012A1 (it) Procedimento per la preparazione di fluazinam
GB2495458B (en) Crystals of carboprost tromethamine and the preparation method as well as the uses thereof
JP2013119547A5 (OSRAM)
TWI562985B (en) Process for the preparation of enolate salts of 4-fluoro-2-hydroxymethylene-3-oxobutyrates
JP2014526571A5 (OSRAM)
IL211266A0 (en) Improved process for the addition of thiolates to alfa, beta-unsaturated carbonyl or sulfonyl compounds